Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company that focuses on the development of drug candidates for the treatment of various central nervous system (CNS) diseases. The company’s lead drug candidate is ANAVEX 2-73, which is currently in Phase III clinical trial for the treatment of Alzheimer’s disease, Phase III clinical trial to treat pediatric patients with Rett syndrome, Phase II clinical trial for the treatment of Parkinson’s disease, and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.

In addition, the company’s drug candidate ANAVEX 3-71 is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications, as well as preclinical clinical trials for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. ANAVEX’s preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.

Anavex Life Sciences Corp. was founded in 2004 and is headquartered in New York, New York. The company is publicly traded on the NASDAQ Global Market under the symbol AVXL. Anavex Life Sciences Corp. has a broad portfolio of small molecule drug candidates that are developed to treat rare and common diseases, such as Alzheimer’s, Parkinson’s, Rett Syndrome, Fragile X Syndrome, Angelman Syndrome, Multiple Sclerosis, Tuberous Sclerosis Complex, Frontotemporal Dementia, and Infantile Spasms. The company is currently focused on advancing its clinical and preclinical programs for the treatment of CNS diseases.